Resverlogix Corp. (TSE:RVX – Get Free Report) hit a new 52-week low during mid-day trading on Thursday . The company traded as low as C$0.04 and last traded at C$0.05, with a volume of 3000 shares traded. The stock had previously closed at C$0.04.
Resverlogix Stock Performance
The firm has a market capitalization of C$8.91 million, a PE ratio of -2.23 and a beta of 0.71. The company has a debt-to-equity ratio of -10.95, a current ratio of 0.13 and a quick ratio of 0.04. The stock has a 50-day moving average price of C$0.05 and a 200-day moving average price of C$0.06.
Resverlogix Company Profile
Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.
See Also
- Five stocks we like better than Resverlogix
- What is a Dividend King?
- Autodesk Designs Value for Investors: Uptrend Set to Continue
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Anheuser-Busch Stock Rallies—Is the King of Beers Back?
- Uptrend Stocks Explained: Learn How to Trade Using Uptrends
- MarketBeat Week in Review – 02/24 – 02/28
Receive News & Ratings for Resverlogix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Resverlogix and related companies with MarketBeat.com's FREE daily email newsletter.
